Recap: Arbutus Biopharma Q2 Earnings

Shares of Arbutus Biopharma ABUS fell 1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 45.65% over the past year to ($0.25), which missed the estimate of ($0.24).

Revenue of $1,514,000 up by 116.29% from the same period last year, which missed the estimate of $1,740,000.

Looking Ahead

Arbutus Biopharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 07, 2020

Time: 07:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/knwh3svj

Price Action

52-week high: $9.02

52-week low: $0.82

Price action over last quarter: Up 184.85%

Company Description

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

ABUS Logo
ABUSArbutus Biopharma Corp
$3.43-1.15%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
72.59
Growth
Not Available
Quality
Not Available
Value
5.21
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...